Literature DB >> 19255821

Genetic analysis of coding SNPs in blood-brain barrier transporter MDR1 in European Parkinson's disease patients.

Claudia Funke1, Anne S Soehn, Juergen Tomiuk, Olaf Riess, Daniela Berg.   

Abstract

Parkinson's disease (PD) is characterized by the loss of dopaminergic neurons and the presence of intracytoplasmic inclusions (Lewy bodies). Iron, which is elevated in the substantia nigra of PD patients, seems to be of pivotal importance, because of its capacity to enhance the amplification of reactive oxygen species. As iron enters and exits the brain via transport proteins in the blood-brain barrier (BBB), these proteins may represent candidates for a genetic susceptibility to PD. P-glycoprotein (P-gp) is one important efflux pump in the BBB. There is evidence that the function of P-gp is impaired in PD patients. In the current study we examined ten coding single nucleotide polymorphisms in the multidrug resistance gene 1 (MDR1) encoding P-gp to assess whether certain genotypes are associated with PD. However, genotyping of 300 PD patients and 302 healthy controls did not reveal a significant association between coding MDR1 gene polymorphisms and PD.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19255821     DOI: 10.1007/s00702-009-0196-y

Source DB:  PubMed          Journal:  J Neural Transm (Vienna)        ISSN: 0300-9564            Impact factor:   3.575


  22 in total

Review 1.  Transcranial sonography in the early and differential diagnosis of Parkinson's disease.

Authors:  D Berg
Journal:  J Neural Transm Suppl       Date:  2006

2.  Effect of MDR1 haplotype on risk of Parkinson disease.

Authors:  Eng-King Tan; Daniel Kam-Yin Chan; Ping-Wing Ng; Jean Woo; Y Y Teo; Kun Tang; Li-Peng Wong; Samuel S Chong; Chris Tan; Hui Shen; Yi Zhao; Caroline G L Lee
Journal:  Arch Neurol       Date:  2005-03

3.  Echogenicity of substantia nigra determined by transcranial ultrasound correlates with severity of parkinsonian symptoms induced by neuroleptic therapy.

Authors:  D Berg; B Jabs; U Merschdorf; H Beckmann; G Becker
Journal:  Biol Psychiatry       Date:  2001-09-15       Impact factor: 13.382

Review 4.  Iron trafficking inside the brain.

Authors:  Torben Moos; Thomas Rosengren Nielsen; Tina Skjørringe; Evan H Morgan
Journal:  J Neurochem       Date:  2007-10-22       Impact factor: 5.372

5.  Association study between iron-related genes polymorphisms and Parkinson's disease.

Authors:  Claire Borie; Francesca Gasparini; Patrice Verpillat; Anne-Marie Bonnet; Yves Agid; Gilles Hetet; Alexis Brice; Alexandra Dürr; Bernard Grandchamp
Journal:  J Neurol       Date:  2002-07       Impact factor: 4.849

6.  Polymorphism in the P-glycoprotein drug transporter MDR1 gene: a possible link between environmental and genetic factors in Parkinson's disease.

Authors:  Marek Droździk; Monika Białecka; Katarzyna Myśliwiec; Krystyna Honczarenko; Jan Stankiewicz; Zbigniew Sych
Journal:  Pharmacogenetics       Date:  2003-05

7.  Echogenicity of the substantia nigra: association with increased iron content and marker for susceptibility to nigrostriatal injury.

Authors:  Daniela Berg; Wolfgang Roggendorf; Ute Schröder; Rüdiger Klein; Thomas Tatschner; Peter Benz; Oliver Tucha; Michael Preier; Klaus W Lange; Karlheinz Reiners; Manfred Gerlach; Georg Becker
Journal:  Arch Neurol       Date:  2002-06

8.  Expression polymorphism of the blood-brain barrier component P-glycoprotein (MDR1) in relation to Parkinson's disease.

Authors:  Taku Furuno; Maria-Teresa Landi; Mauro Ceroni; Neil Caporaso; Ilaria Bernucci; Giuseppe Nappi; Emilia Martignoni; Elke Schaeffeler; Michel Eichelbaum; Matthias Schwab; Ulrich M Zanger
Journal:  Pharmacogenetics       Date:  2002-10

9.  Blood-brain barrier P-glycoprotein function is not impaired in early Parkinson's disease.

Authors:  A L Bartels; B N M van Berckel; M Lubberink; G Luurtsema; A A Lammertsma; K L Leenders
Journal:  Parkinsonism Relat Disord       Date:  2008-03-05       Impact factor: 4.891

Review 10.  The etiopathogenesis of Parkinson disease and suggestions for future research. Part I.

Authors:  Irene Litvan; Glenda Halliday; Mark Hallett; Christopher G Goetz; Walter Rocca; Charles Duyckaerts; Yoav Ben-Shlomo; Dennis W Dickson; Anthony E Lang; Marie-Francoise Chesselet; William J Langston; Donato A Di Monte; Thomas Gasser; Theo Hagg; John Hardy; Peter Jenner; Eldad Melamed; Richard H Myers; Davis Parker; Donald L Price
Journal:  J Neuropathol Exp Neurol       Date:  2007-04       Impact factor: 3.685

View more
  4 in total

Review 1.  Alzheimer's and ABC transporters--new opportunities for diagnostics and treatment.

Authors:  Jens Pahnke; Oliver Langer; Markus Krohn
Journal:  Neurobiol Dis       Date:  2014-04-16       Impact factor: 5.996

2.  Genetic variability in ABCB1, occupational pesticide exposure, and Parkinson's disease.

Authors:  Shilpa Narayan; Janet S Sinsheimer; Kimberly C Paul; Zeyan Liew; Myles Cockburn; Jeff M Bronstein; Beate Ritz
Journal:  Environ Res       Date:  2015-10-19       Impact factor: 6.498

Review 3.  Glutathione metabolism and Parkinson's disease.

Authors:  Michelle Smeyne; Richard Jay Smeyne
Journal:  Free Radic Biol Med       Date:  2013-05-08       Impact factor: 7.376

4.  Genetic association of NOS1 exon18, NOS1 exon29, ABCB1 1236C/T, and ABCB1 3435C/T polymorphisms with the risk of Parkinson's disease: A meta-analysis.

Authors:  Hongbin Huang; Cong Peng; Yong Liu; Xu Liu; Qicong Chen; Zunnan Huang
Journal:  Medicine (Baltimore)       Date:  2016-10       Impact factor: 1.889

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.